NAV5001 + DaTscan
Phase 3Withdrawn 2 views this week 0 watching💤 Quiet
Interest: 22/100
22
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Parkinson's Syndrome
Conditions
Parkinson's Syndrome
Trial Timeline
Apr 1, 2017 → Mar 1, 2018
NCT ID
NCT01950468About NAV5001 + DaTscan
NAV5001 + DaTscan is a phase 3 stage product being developed by Navidea Biopharmaceuticals for Parkinson's Syndrome. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01950468. Target conditions include Parkinson's Syndrome.
What happened to similar drugs?
20 of 20 similar drugs in Parkinson's Syndrome were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
17
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01950468 | Phase 3 | Withdrawn |
Competing Products
20 competing products in Parkinson's Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| UB-312 + Placebo | Vaxxinity | Phase 1 | 19 |
| piclozotan + 0.9% sodium chloride (normal saline) | Daiichi Sankyo | Phase 2 | 35 |
| E2007 | Eisai | Phase 3 | 32 |
| ARICEPT | Eisai | Phase 3 | 40 |
| Perampanel | Eisai | Phase 3 | 32 |
| GPI 1485 | Eisai | Phase 2 | 35 |
| E2007 | Eisai | Phase 3 | 40 |
| Prior Donepezil 5mg + Prior Donzepezil 10mg + Prior Placebo | Eisai | Phase 3 | 40 |
| perampanel + placebo | Eisai | Phase 2 | 27 |
| Lemborexant + placebo | Eisai | Approved | 50 |
| Placebo + E2007 + E2007 | Eisai | Phase 3 | 32 |
| E2007 + E2007 + E2007 | Eisai | Phase 2 | 35 |
| E2007 | Eisai | Phase 2 | 35 |
| E2007 | Eisai | Phase 2 | 27 |
| E2007 | Eisai | Phase 2 | 27 |
| 2 mg perampanel + 4 mg perampanel + placebo comparator | Eisai | Phase 3 | 40 |
| Istradefylline (KW-6002) | Kyowa Kirin | Phase 2 | 35 |
| Istradefylline 20 mg or 40 mg | Kyowa Kirin | Phase 3 | 40 |
| Istradefylline (KW-6002) | Kyowa Kirin | Phase 3 | 40 |
| Perampanel | Eisai | Phase 2 | 27 |